Innovate gets approval from FDA for MediBeacon TGFY
Hawkinsight
2025-01-20 14:45:50
2.20W
Innovate (NYSE:VATE) announced today that the U.S. Food and Drug Administration has approved the MediBeacon TGFR for the assessment of kidney function in patients with normal or impaired renal function. The TGFR met its primary efficacy endpoint as per agreement with the FDA by demonstrating a P30 value of 94% while recruiting patients with a range of GFR values and skin tones. Source: Press Release
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.